This record was last updated March 12, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the treatments with both abiraterone acetate and docetaxel, or who are not suitable for docetaxel treatment.
Protocol Amendment History
9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-02-21; most recent amendment 2025-03-10.
Status change: Not Yet Recruiting → Recruiting2019-07-24